ROIV
Closed
Roivant Sciences Ltd
10.94
-0.33 (-2.93%)
Last Update: 01 Jul 2025 23:06:00
Yesterday: 11.27
Day's Range: 10.92 - 11.32
Send
sign up or login to leave a comment!
When Written:
7.38
Roivant Sciences Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases with high unmet medical needs. The company was founded in 2014 by Vivek Ramaswamy and is headquartered in Basel, Switzerland.
Roivant Sciences operates as a holding company with subsidiary companies that are focused on specific therapeutic areas, including neurology, oncology, dermatology, and women's health. The company's subsidiaries include Axovant Sciences, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Dermavant Sciences, and Metavant Sciences.
Roivant Sciences has a unique business model that involves acquiring and developing drugs that have been abandoned or deprioritized by other pharmaceutical companies. The company then invests in the clinical development of these drugs and seeks to bring them to market as quickly as possible.
In 2018, Roivant Sciences raised $1.1 billion in funding from investors, including SoftBank Vision Fund, to support its drug development efforts. As of 2021, the company has several drugs in clinical development and has received FDA approval for several others.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Roivant Sciences operates as a holding company with subsidiary companies that are focused on specific therapeutic areas, including neurology, oncology, dermatology, and women's health. The company's subsidiaries include Axovant Sciences, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Dermavant Sciences, and Metavant Sciences.
Roivant Sciences has a unique business model that involves acquiring and developing drugs that have been abandoned or deprioritized by other pharmaceutical companies. The company then invests in the clinical development of these drugs and seeks to bring them to market as quickly as possible.
In 2018, Roivant Sciences raised $1.1 billion in funding from investors, including SoftBank Vision Fund, to support its drug development efforts. As of 2021, the company has several drugs in clinical development and has received FDA approval for several others.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








